Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
Coronavirus Vaccine Roundup, Early September
07:39am, Friday, 04'th Sep 2020
Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated v
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
10:06am, Wednesday, 02'nd Sep 2020
The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
Novavax: COVID-19 Gave It Fuel, But It's Running Near Empty
02:15pm, Monday, 31'st Aug 2020
NVAX had run over 4,000% YTD at its peak. COVID-19 vaccine hype is giving it some much-needed fuel after failing two late-stage clinical trials in 2016 and 2019.
COVID-19: The Real Results Are A Long Way Away
03:47pm, Wednesday, 19'th Aug 2020
Hope for a successful vaccine by the winter is fueling trials at a record pace. WHO data shows that there are 38 candidates in clinical trials, but only 8 are in Phase 2 and Phase 3.
Stocks on the Move: Curevac gains 249% on first day of trading, Nvidia stock rises on Susquehanna target boost
05:04pm, Monday, 17'th Aug 2020
The On the Move panel discuss today's Stocks on the Move: Curevac and Nvidia.
CureVac Stock Soared 249% on Its First Day of Trading. Here’s What It’s Doing for an Encore.
01:25pm, Monday, 17'th Aug 2020
Shares of CureVac, which specializes in the messenger RNA technology that is the basis of many of the leading Covid-19 vaccine programs, is set to soar on the second trading day.
CureVac's Impressive Debut, And Other News: The Good, Bad And Ugly Of Biopharma
09:13am, Monday, 17'th Aug 2020
CureVac makes impressive debut, stock jumps 175%. Masimo receives FDA clearance for mechanically ventilated patients.
Wall Street Breakfast: Trump Eyeing More Chinese Firms For Possible Action
07:01am, Monday, 17'th Aug 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
New Zealand Delays Elections; U.S. Cases Slow: Virus Update
11:09pm, Sunday, 16'th Aug 2020
(Bloomberg) -- New Zealand delayed its national election by four weeks over concerns the outbreak could disrupt the campaign and balloting. U.S. deaths exceeded 1,000 for the fifth consecutive day. An
U.S. Cases Slow as Deaths Pass 1,000 for Fifth Day: Virus Update
06:32pm, Sunday, 16'th Aug 2020
(Bloomberg) -- The U.S. added 47,813 virus cases, a 0.9% rise that compares with a 1% increase over the previous week. Nationwide deaths exceeded 1,000 for the fifth consecutive day. A measure of inte
U.S. IPO Weekly Recap: Coronavirus Vaccine Developer CureVac Pops 249% In A 4-IPO Week
03:32pm, Saturday, 15'th Aug 2020
Four IPOs and six SPACs entered the public markets this past week led by CureVac, which posted the largest first-day pop for a US IPO since 2005.
Covid Vaccine Contender CureVac More Than Triples in Debut
08:39pm, Friday, 14'th Aug 2020
(Bloomberg) -- CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.It was the best f
COVID-19 vaccine maker CureVac pops 200% in debut
06:43pm, Friday, 14'th Aug 2020
Yahoo Finance's Anjalee Khemlani and Zack Guzman discuss COVID-19 vaccine maker Curevac's public debut and the UK Government signing vaccine deals with J&J and Novavax.
CureVac's stock debuts at nearly triple the IPO price
04:21pm, Friday, 14'th Aug 2020
Shares of CureVac BV blasted off in their public debut Friday, as they opened at nearly triple the $16 initial public offering price. The Germany-based clinical stage biotechnology company raised $21
CureVac raises $213.3 million in IPO after pricing at $16 a share, high end of proposed range
10:42am, Friday, 14'th Aug 2020
CureVac BV, a clinical-stage biotech headquartered in Germany, priced its initial public offering on Friday at $16 a share, the high end of its proposed range. The company sold 13.3 million shares to
